GP-531 adenosine regulating agent: GNSA began a 50-patient Phase II trial with its second-generation adenosine regulating agent.

Gensia Inc. (GNSA), San Diego, Calif. Product: GP-531 adenosine regulating agent Indication: Cardiovascular disease/myocardial ischemia Status: GNSA began a 50-patient Phase II trial with its second-g...